



## PHARMACY

### Site of Care Change

#### FASENRA AND NUCALA

Effective March 1, 2021, coverage for Fasenra (J0517) and Nucala (J2812) will be as self-administered medication under the pharmacy benefit and must be processed through the pharmacy benefit manager. Patients currently receiving in-office treatments of Fasenra or Nucala will need to transition to self-administered medication under the pharmacy benefit for coverage. For teaching purposes, there will be coverage under the medical benefit limited to one in-office treatment per lifetime.

### Exclusion Updates

#### NEULASTA AND NEULASTA ONPRO

Effective March 1, 2021, Neulasta (J2505) and Neulasta OnPro (J2505) will move from preauthorization required to excluded. The following biosimilars will be covered upon preauthorization approval:

- Ziextenzo (J3590)
- Fulphila (Q5108)
- Udenyca (Q5111)

In addition, coverage for Ziextenzo (J3590), Fulphila (Q5108) and Udenyca (Q5111) will be as self-administered medication under the pharmacy benefit and must be processed through the pharmacy benefit manager. Patients currently receiving in-office treatments of Ziextenzo, Fulphila or Udenyca will need to transition to self-administered medication under the pharmacy

benefit for coverage. For teaching purposes, there will be coverage under the medical benefit limited to one in-office treatment per lifetime.

### General Exclusion

Effective December 4, 2020, the general exclusion of new FDA-approved drugs will be applied to ALL drugs and extended from a 6-month period to a 1-year period post market availability.

### Emergency Use Authorization of COVID-19 Infusion Medicines

Through the federally run allocation program, medications for COVID-19 treatment have been purchased by the federal government. They are offered at no cost to states, sites of care and patients, and therefore will not be reimbursed by WEA Trust. Services and ancillary expenses necessary to administer the infusion are the responsibility of the individual site of care and can be billed to WEA Trust for reimbursement.

The following medications have all been granted Emergency Use Authorization by the FDA for the treatment of COVID-19:

- Veklury (Remdesivir) - in hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg with confirmed COVID-19
- Olumiant (Baricitinib)
- Bamlanivimab (LY-CoV555)
- Casirivimab
- Imdevimab

# PROVIDER NETWORK UPDATE

## Smart Choice MRI

Effective November 23, 2020, Smart Choice MRI is no longer a network provider for WEA Trust and has exited the market. As a result, the gift card incentive program for imaging services through Smart Choice MRI is no longer available. While some locations may continue to operate under a different corporate entity, members are advised to confirm network status with WEA Trust prior to receiving care at any such facility.



# REMINDERS

## Telemedicine Coverage

Video conferencing, Telemedicine, or Telehealth Services are covered under the health policy if the service is provided in a manner that allows both verbal and visual interaction between the physician and patient, meaning the patient and the provider can both see and speak to one another at the same time during the visit.

**Audio-only telephone communication**, where the patient is only speaking to a provider over the telephone, **is not a covered benefit**. We encourage members to request their provider arranges all telemedicine visits to have an audio and visual component to the interaction to ensure the visit is covered by WEA Trust.

**Please Note:** Due to the COVID-19 pandemic, WEA Trust has made the exception to allow coverage for audio-only telephone communication for outpatient mental health services and autism services and/or therapy.



# EDI TRANSACTIONS

## New EDI Clearinghouse

WEA Trust currently utilizes Optum Netwerkes as our Electronic Data Interchange (EDI) clearinghouse. WEA Trust will be discontinuing the use of Optum Netwerkes and migrate to Availity as our new clearinghouse. By the end of January 2021, all EDI transactions will be through Availity.

270/271 – Real Time Eligibility

276/277 – Claim Status Response

835 – Remittance File

837 – Claim File

The EDI Payor ID of 39151 will remain the same.

WEA Trust is working diligently with both clearinghouses to make sure this transition is seamless for our provider partners.

# CREDENTIALING


Contracted providers must complete the credentialing process and receive approval for network participation prior to rendering services to WEA Trust members. Services provided before the successful completion of the credentialing process will be denied and may not be billed to the member.

## PROVIDER CHANGES

Network providers are responsible for notifying WEA Trust of any updates to their provider organization, business practice, or practitioners. Please use our Provider Update Form, found on our website at [WEAtrust.com/provider/update-provider-info](https://WEAtrust.com/provider/update-provider-info).

Provide a minimum of 30 days' prior notice for any such changes, including but not limited to:

- Change in ownership, operations, or incorporation status
- Change in Tax ID number or legal business name
- Acquisition of other medical practice or entity
- Change in accreditation, licensure or eligibility status
- Change in billing or other contact information
- Change in service location
- Practitioner joining or leaving your organization
- Change in practitioner name, credentials, or specialty



**Thank you  
Providers.**



### Let's Keep in Touch!

Stay updated with WEA Trust news and reminders.

**Follow us on social media.**

**Stay connected with us on Facebook.**

[FACEBOOK.COM/WEATRUST](https://FACEBOOK.COM/WEATRUST)